Leflunomide as a cause of collagenous colitis: An entity to consider

Paulina Núñez; Rodrigo Quera; Lilian Flores; Luis Contreras

doi:10.17235/reed.2021.8015/2021

Leflunomide as a cause of collagenous colitis: An entity to consider

Paulina Núñez
, Rodrigo Quera
, Lilian Flores
, Luis Contreras

Clínica Universidad de los Andes

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.

Original language	English
Pages (from-to)	735-736
Number of pages	2
Journal	Revista Espanola de Enfermedades Digestivas
Volume	113
Issue number	10
DOIs	https://doi.org/10.17235/reed.2021.8015/2021
State	Published - Oct 2021

Keywords

Chronic diarrhea
Collagenous colitis
Leflunomide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.17235/reed.2021.8015/2021

Cite this

@article{c5b1dfb81ab84a448c83c3b035a215c0,

title = "Leflunomide as a cause of collagenous colitis: An entity to consider",

abstract = "Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 \% of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.",

keywords = "Chronic diarrhea, Collagenous colitis, Leflunomide, Leflunomide, Collagenous colitis",

author = "Paulina N{\'u}{\~n}ez and Rodrigo Quera and Lilian Flores and Luis Contreras",

year = "2021",

month = oct,

doi = "10.17235/reed.2021.8015/2021",

language = "English",

volume = "113",

pages = "735--736",

journal = "Revista Espanola de Enfermedades Digestivas",

issn = "1130-0108",

publisher = "ARAN Ediciones S.L",

number = "10",

}

TY - JOUR

T1 - Leflunomide as a cause of collagenous colitis

T2 - An entity to consider

AU - Núñez, Paulina

AU - Quera, Rodrigo

AU - Flores, Lilian

AU - Contreras, Luis

PY - 2021/10

Y1 - 2021/10

N2 - Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.

AB - Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.

KW - Chronic diarrhea

KW - Collagenous colitis

KW - Leflunomide

KW - Collagenous colitis

UR - https://www.scopus.com/pages/publications/85117190048

U2 - 10.17235/reed.2021.8015/2021

DO - 10.17235/reed.2021.8015/2021

M3 - Letter

C2 - 33866790

AN - SCOPUS:85117190048

SN - 1130-0108

VL - 113

SP - 735

EP - 736

JO - Revista Espanola de Enfermedades Digestivas

JF - Revista Espanola de Enfermedades Digestivas

IS - 10

ER -

Leflunomide as a cause of collagenous colitis: An entity to consider

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this